Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Elanco Expects Reduction Of Approximately $5M - $10M Of Adjusted EBITDA In 2024 Related To TriRx Situation

Author: Benzinga Newsdesk | September 13, 2024 07:36am

Despite this headwind, Elanco continues to expect to deliver its full year adjusted EBITDA guidance of $900 million to $940 million.

Posted In: ELAN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist